Pilot Trial of IV Psilocin Reports 73% Drop in Binge Episodes Among Six Treatment-Resistant Patients

The trial administered TRP-8803, a proprietary IV psilocin formulation, to six adults averaging 2.3 weekly binges who had failed prior therapies. Post-treatment tracking over 12 weeks recorded a 73% overall reduction in episodes, alongside 50% lower anxiety scores, 42% lower depression scores, and 61% better quality-of-life ratings. No serious adverse events were noted in the brief report. The design lacked a control arm, raising the possibility that expectancy or nonspecific support contributed to gains.

Psychedelic research for eating disorders remains sparse; prior work has focused mainly on anorexia nervosa or major depression. This pilot aligns with emerging signals that 5-HT2A agonism may disrupt rigid reward patterns, yet it supplies only within-subject change data without placebo subtraction or neuroimaging correlates. The 12-week durability observation is encouraging but short relative to the 20-year illness duration described.

Swinburne and Entropy are now recruiting a second cohort to test a shorter infusion schedule aimed at scalability. A future randomized phase 2 trial with blinded raters and longer follow-up will be required to separate drug-specific effects from nonspecific factors and to establish whether benefits persist beyond three months.